Bioventix PLC (BVXP) Price Target Increased to GBX 1,450 by Analysts at FinnCap
Bioventix PLC (LON:BVXP) had its price objective lifted by FinnCap from GBX 1,350 ($16.45) to GBX 1,450 ($17.67) in a research note published on Monday morning. FinnCap currently has a corporate rating on the biotechnology company’s stock.
Bioventix PLC (LON:BVXP) opened at 1449.00 on Monday. Bioventix PLC has a 12 month low of GBX 899.50 and a 12 month high of GBX 1,600.00. The firm’s 50-day moving average price is GBX 1,169.99 and its 200 day moving average price is GBX 1,047.77. The stock’s market cap is GBX 73.19 million.
The business also recently announced a dividend, which will be paid on Friday, November 11th. Stockholders of record on Thursday, October 27th will be given a dividend of GBX 46 ($0.56) per share. The ex-dividend date of this dividend is Thursday, October 27th. This represents a dividend yield of 3.15%. This is an increase from Bioventix PLC’s previous dividend of $16.50.
Bioventix PLC Company Profile
Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.